Abstract:Objective:To explore the efficacy and safety of intermittent infusion of ilaprazole sodium and high-dose continuous infusion of esomeprazole sodium in preventing rebleeding in patients with peptic ulcer bleeding after successful endoscopic hemostasis.Methods:This is a multi-center, interval randomized, double-blind, double-dummy, parallel controlled study. From March 3rd to June 15th, 2021, 151 patients with high risk of peptic ulcer bleeding and successfully underwent endoscopic hemostasis from 33 hospitals including the First Affiliated Hospital of Zhejiang University School of Medicine were enrolled. Patients were interval randomly divided into the trial group (74 cases) and the control group (77 cases). Patients in the trial group received intermittent intravenous infusion of ilaprazole sodium once daily (20 mg administered as a 60 min intravenous infusion on day 1, and 10 mg administered as a 30 min intravenous infusion on day 2 and 3); patients in the control group received continuous intravenous infusion of esomeprazole sodium for 72 h (esomeprazole sodium 80 mg at first dose in half an hour, and 8 mg per hour continuous intravenous infusion for 71.5 h). After intravenous infusion treatment, patients of both groups were given oral ilaprazole enteric-coated tablets, 10 mg each time, once a day for 4 d. The rebleeding rate after 72 h and within 7 d after treatment and the proportion of patients who received endoscopic retreatment or surgery due to rebleeding within 72 h after treatment were analysised based on the full analysis set (72 cases in the trial group and 75 cases in the control group); and the incidence rate of adverse reactions was observed in the two groups based on the safety analysis set (74 cases in the trial group and 76 cases in the control group). Chi-square test or Fisher exact probability test was used for statistical analysis.Results:There was no rebleeding case in the trial group within 72 h and 1 case of rebleeding within 7 d (1.39%, 1/72). In the control group, there was 1 case of rebleeding (1.33%, 1/75) within 72 h and 4 cases of rebleeding (5.33%, 4/75) within 7 d. There was no significant difference in rebleeding rate either after 72 h or within 7 d after treatment between the two groups (both P>0.05). Within 72 h of treatment, no patients in both groups needed endoscopic or surgical retreatment due to rebleeding. Adverse reactions occurred in 5 cases (6.8%, 5/74) and 6 cases (7.9%, 6/76) in the trial group and control group, respectively, which recovered spontaneously without treatment. No serious adverse reactions occurred in both groups. Conclusion:In patients with high-risk peptic ulcer bleeding with successful endoscopic hemostasis, intermittent intravenous infusion of ilaprazole sodium has similar efficacy and safety as continuous high-dose intravenous infusion of esomeprazole sodium, but the dosage of intermitten regimen is less, the administration is more convenient, and it is worthy of clinical promotion.

Comparison of the inhibitive effect on gastric acid between single dose rabeprazole and esomeprazole in healthy volunteers

Acid-suppressive Effects of Rabeprazole: Comparing 10mg and 20mg Twice Daily in Japanese Helicobacter Pylori-Negative and -Positive CYP2C19 Extensive Metabolisers

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

Study of esomeprazole and rabeprazole on 24-hour intragastric acid control in healthy volunteers

The controlled study of efficacy and safety of infusion of ilaprazole sodium versus esomeprazole sodium in prevention of peptic ulcer rebleeding

Comparison on relief of symptoms and acid suppression of Rabeprazole and Omeprazole on reflux esophagitis in aged

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Effect of Omeprazole in treating peptic ulcers of children

Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole.

Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis

The Effect of Low-Dose Omeprazole on 24-Hour Intragastric Ph in Healthy Human Subjects

Efficacy of Rabeprazole Versus Omerpazole for Acid Suppression in Patients with Duodenal Ulcer: a Multicenter, Randomized, Double-Blind Clinical Trial

Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes

Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori

Comparison of the Gastric Acid Inhibition Function among Lansoprazole, Pantoprazole, and Their Respective Stereoisomers in Healthy Chinese Subjects

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Effect of esomeprazole on intragastric pH in healthy Chinese with different CYP2C19 genotypes

<TITLE>COMPARATIVE EFFECTS OF ESOMEPRAZOLE AND OMEPRAZOLE IN TREATING REFLUX ESOPHAGITIS OF THE AGED

The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan

Optimal suppression of gastric acid and ulcer healing in children with peptic ulcer

The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH